Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $235.35
    +2.52 (+1.08%)

    Market Cap: $34.40B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(36/39)
    Avg Surprise
    +11.29%
    Streak
    17 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.04
    Range$1.44 - $2.67
    26 analysts
    EPS RevisionsNo revisions (7d)
    1
    20
    30d
    EPS Estimate DriftChange to current
    90d ago$3.71-45.1%
    60d ago$2.10-3.0%
    30d ago$2.03+0.3%
    7d ago$2.03+0.3%
    Current$2.04
    Revenue Consensus
    $2.6B
    Range$2.5B - $2.7B
    26 analysts
    Period ending Dec 31, 2026
    EPS Consensus$5.53
    Range$4.98 - $9.37
    33 analysts
    Revenue Consensus
    $3.1B
    Range$2.8B - $3.3B
    32 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$5.53---
    Sep 26EST
    		-$2.04---
    Jun 26
    Reported Jul 29
    		$3.60$3.04+18.42%Beat-34.2%
    Mar 26
    Reported Apr 29
    		$3.57$2.89+23.53%Beat+18.2%
    Dec 25
    Reported Feb 6
    		$1.99$1.62+22.84%Beat-42.2%
    Sep 25
    Reported Oct 30
    		$4.81$3.88+23.97%Beat+17.9%
    Jun 25
    Reported Jul 31
    		$5.47$3.88+40.98%Beat+3.6%
    Mar 25
    Reported May 1
    		$3.02$2.95+2.37%Beat-17.7%
    Dec 24
    Reported Feb 12
    		$3.44$3.36+2.38%Beat+4.2%
    Sep 24
    Reported Oct 30
    		$4.08$3.79+7.65%Beat-6.4%
    Jun 24
    Reported Aug 1
    		$5.28$4.03+31.02%Beat+31.3%
    Mar 24
    Reported Apr 24
    		$3.67$3.46+6.07%Beat+7.9%
    Dec 23
    Reported Feb 13
    		$3.30$3.18+3.77%Beat-18.5%
    Sep 23
    Reported Nov 8
    		$4.36$3.98+9.55%Beat-8.6%
    Jun 23
    Reported Jul 25
    		$4.02$3.76+6.91%Beat-23.4%
    Mar 23
    Reported Apr 25
    		$3.40$3.28+3.66%Beat-6.1%
    Dec 22
    Reported Feb 15
    		$4.05$3.48+16.38%Beat+19.5%
    Sep 22
    Reported Oct 25
    		$4.77$4.13+15.50%Beat+0.0%
    Jun 22
    Reported Jul 20
    		$5.25$4.07+28.99%Beat-7.6%
    Mar 22
    Reported May 3
    		$3.62$4.36-16.97%Miss-32.2%
    Dec 21
    Reported Feb 3
    		$3.39$3.37+0.59%Beat-26.0%
    Sep 21
    Reported Oct 20
    		$4.77$4.10+16.34%Beat-46.0%
    Jun 21
    Reported Jul 22
    		$5.68$4.60+23.48%Beat-44.6%
    Mar 21
    Reported Apr 22
    		$5.34$4.94+8.10%Beat-41.6%
    Dec 20
    Reported Feb 3
    		$4.58$4.80-4.58%Miss-45.1%
    Sep 20
    Reported Oct 21
    		$8.84$8.05+9.81%Beat-3.6%
    Jun 20
    Reported Jul 22
    		$10.26$8.00+28.25%Beat+12.1%
    Mar 20
    Reported Apr 22
    		$9.14$7.69+18.86%Beat+30.9%
    Dec 19
    Reported Jan 30
    		$8.34$8.08+3.22%Beat+19.3%
    Sep 19
    Reported Oct 22
    		$9.17$8.27+10.88%Beat+23.9%
    Jun 19
    Reported Jul 23
    		$9.15$7.53+21.51%Beat+57.8%
    Mar 19
    Reported Apr 24
    		$6.98$6.96+0.29%Beat+15.4%
    Dec 18
    Reported Jan 29
    		$6.99$6.72+4.02%Beat+32.9%
    Sep 18
    Reported Oct 23
    		$7.40$6.76+9.47%Beat+17.3%
    Jun 18
    Reported Jul 24
    		$5.80$5.14+12.84%Beat+15.1%
    Mar 18
    Reported Apr 24
    		$6.05$5.94+1.85%Beat+16.3%
    Dec 17
    Reported Jan 25
    		$5.26$5.45-3.49%Miss+4.4%
    Sep 17
    Reported Oct 24
    		$6.31$5.72+10.31%Beat-
    Jun 17
    Reported Jul 25
    		$5.04$4.37+15.33%Beat-
    Mar 17
    Reported Apr 25
    		$5.20$4.97+4.63%Beat-
    Dec 16
    Reported Jan 26
    		$5.04$4.96+1.61%Beat-

    Key Metrics

    Valuation
    P/E Ratio16.85EV/EBITDA18.16x
    Price/FCF12.89xFCF Yield7.76%
    Profitability
    Profit Margin8.32%Operating Margin25.10%
    ROE4.58%ROIC3.06%
    Financial Health
    Debt/Equity0.43xInterest CoverageN/A
    Current Ratio1.87xQuick Ratio1.26x
    Trading Statistics
    Beta0.09Avg Volume1.26M
    52-Week High$238.2452-Week Low$138.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$225.91
    SMA 20$225.25
    SMA 50$219.18
    SMA 200$197.55
    EMA 10$228.02
    EMA 20$225.26
    EMA 50$219.37
    EMA 200$197.60

    MACD

    Line: 3.37Signal: 2.57Hist: 0.80

    ADX

    ADX: 22.8+DI: 35.7-DI: 15.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon DownN/A
    PSAR$217.05

    Bollinger Bands

    Upper Band$234.99
    Lower Band$215.51
    %B Position864%(Upper)
    Band Width1.02

    RSI (14-Day)

    Neutral
    66.1

    Momentum Oscillators

    Stoch %K70.7
    Stoch %D66.0
    Williams %R-22.3
    ROC (10d)5.6%
    Momentum12.53
    CCI (20d)208.1
    MFI (14d)58.1

    Volatility Measures

    ATR (14d)$6.48(2.8%)
    StdDev (20d)4.87
    Hist Vol23.3%(Moderate)

    Volume Flow

    VWAP$237.19
    OBV49.2M
    AD Line20.2M
    CMF (20d)-0.185

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.2x
    VWMA (20d)$225.19

    Pivot Points

    R3$241.55
    R2$237.88
    R1$235.35
    Pivot Point$231.68
    S1$229.15
    S2$225.48
    S3$222.95

    Advanced Oscillators

    TSI17.62
    Ultimate Osc45.2
    KST36.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.74B$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B$2.47B$2.46B$2.29B$2.39B$2.53B
    Cost of Revenue$776.90M$661.00M$495.50M$674.40M$605.00M$629.30M$583.50M$638.70M$546.00M$542.20M$618.30M$659.60M
    Gross Profit$1.96B$1.82B$1.78B$1.86B$2.04B$1.80B$1.87B$1.83B$1.92B$1.75B$1.77B$1.87B
    Operating Expenses$1.83B$1.44B$1.85B$1.30B$1.28B$1.49B$1.58B$1.38B$1.22B$1.28B$1.48B$2.01B
    R&D$693.60M$573.00M$731.80M$438.20M$445.60M$634.80M$532.30M$542.70M$513.90M$452.90M$570.90M$736.30M
    SG&A$709.70M$607.30M$682.50M$594.80M$583.80M$572.50M$680.00M$588.40M$553.80M$581.50M$608.50M$788.20M
    Operating Income$132.40M$377.70M$-69,200,000$557.30M$757.20M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$13.20M$0$0$0$0$0$0$0
    Income Before Tax$132.40M$377.70M$-56,000,000$557.30M$744.00M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    Income Tax Expense$34.90M$58.20M$-7,100,000$90.80M$109.20M$70.70M$24.80M$62.50M$115.10M$71.40M$42.70M$-72,900,000
    Net Income$97.50M$319.50M$-62,100,000$466.50M$648.00M$240.50M$266.70M$388.50M$583.60M$393.40M$248.90M$-68,300,000
    EBITDA$571.30M$689.70M$206.40M$821.00M$1.00B$545.80M$520.40M$684.70M$947.70M$656.40M$463.20M$-16,200,000
    EBIT$132.40M$377.70M$-69,200,000$557.30M$757.20M$311.20M$291.50M$451.00M$698.70M$464.80M$291.60M$-141,200,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BIIB

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share

    Royalty Pharma plc has declared a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on December 10, 2026, to shareholders of record as of November 13, 2026. The company, established in 1996...

    Quiver Quantitative•10/16/26•Neutral

    Three-year-old boy shows early improvement after receiving investigational brain tumor treatment NEO100 in Abu Dhabi

    NeOnc Technologies reported early clinical improvement in a three-year-old boy with an aggressive brain tumor, who received the investigational intranasal treatment NEO100 under compassionate use in Abu Dhabi. While...

    Pluang•10/16/26•Somewhat-Bullish

    Biogen-backed Estuary nabs $93M for liver disease gene therapy

    Estuary Biotherapeutics, a genetic medicines developer with roots from Yale School of Medicine research and a management team including former Biogen leaders...

    BioPharma Dive•10/16/26•Somewhat-Bullish

    Biogen-backed Estuary nabs $93M for liver disease gene therapy

    Estuary Biotherapeutics, a California-based genetic medicines developer, has launched with $93 million in Series A funding...

    Yahoo Finance•10/16/26•Somewhat-Bullish

    Corbus Pharmaceuticals stock costs EUR 3.86 with volume 36.43 percent above average

    Corbus Pharmaceuticals (CRBP) stock was trading at EUR 3.86 on October 15, 2026, with a trading volume of 1,089,233 shares, which is 36.43% above its average. The company, focused on oncology and obesity treatments...

    ad-hoc-news.de•10/15/26•Neutral

    BIIB Valuation and Fair Value

    P/E
    16.8x
    Forward P/E
    13.9x
    EV/EBITDA
    18.2x
    P/FCF
    12.9x
    PEG
    2.4x
    P/B
    1.8x
    See GNG's fair value

    BIIB Profitability: Margins, ROIC and FCF

    Gross margin
    74.0%
    Operating margin
    25.1%
    Net margin
    8.3%
    ROIC
    3.1%
    ROE
    4.6%
    FCF margin
    26.9%
    FCF yield
    7.8%

    BIIB Competitors

    CompanyTicker
    Centene CorpCNC
    Royalty Pharma PlcRPRX
    BeiGene, Ltd.ONC
    ResMed IncRMD
    IDEXX Laboratories IncIDXX
    Mettler-Toledo International IncMTD
    Illumina IncILMN
    DexCom IncDXCM

    Sector: Healthcare

    BIIB Analyst Ratings

    Consensus
    Buy
    Analysts
    35
    Strong Buy
    3
    Buy
    19
    Hold
    12
    Sell
    1
    Strong Sell
    0

    BIIB Bull Case vs Bear Case

    Bull case

    • BIIB converts 26.9% of revenue into free cash flow.
    • BIIB beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 62.9% of BIIB's analyst ratings are Buy or Strong Buy.

    BIIB Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    17.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.04
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 20 down

    Frequently Asked Questions About BIIB

    Does BIIB pay dividends?

    Biogen Inc (BIIB) does not currently pay a regular dividend.

    What is BIIB's P/E ratio?

    Biogen Inc has a price-to-earnings (P/E) ratio of 16.85.

    What is BIIB's market cap?

    Biogen Inc (BIIB) has a market capitalization of $34.40B with a current stock price of $235.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In